Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-114075
Filing Date
2026-03-18
Accepted
2026-03-18 16:29:45
Documents
107
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K fdmt-20251231.htm   iXBRL 10-K 3968327
2 EX-4.1 fdmt-ex4_1.htm EX-4.1 57927
3 EX-10.16 fdmt-ex10_16.htm EX-10.16 17006
4 EX-10.21 fdmt-ex10_21.htm EX-10.21 33692
5 EX-10.22 fdmt-ex10_22.htm EX-10.22 118120
6 EX-10.23 fdmt-ex10_23.htm EX-10.23 108139
7 EX-10.24 fdmt-ex10_24.htm EX-10.24 928814
8 EX-23.1 fdmt-ex23_1.htm EX-23.1 2611
9 EX-31.1 fdmt-ex31_1.htm EX-31.1 22508
10 EX-31.2 fdmt-ex31_2.htm EX-31.2 22382
11 EX-32.1 fdmt-ex32_1.htm EX-32.1 13955
12 GRAPHIC img227872923_0.jpg GRAPHIC 82306
  Complete submission text file 0001193125-26-114075.txt   16758141

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fdmt-20251231.xsd EX-101.SCH 2186214
111 EXTRACTED XBRL INSTANCE DOCUMENT fdmt-20251231_htm.xml XML 2642285
Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Filer) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39782 | Film No.: 26769549
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)